Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Furthermore, when the obesogenic status was reduced, the expression of amylin and GLP-1 receptors in the DVC remained stable, suggesting that even in a weight-reduced state form obesity, the DVC GLP-1R and amylin receptors theoretically remain as viable drug targets for sustaining weight loss with continued pharmacotherapy
However, these are often associated with side effects such as dizziness, anxiety, depression, nervousness, and diarrhea
Availability depends on patent status and regulatory approvals
Exclusions were patients with type 1, secondary, or gestational diabetes or missing data
US$ 28.32
US$ 21.40
US$ 21.47
US$ 28.64
US$ 20.96
US$ 28.33
US$ 28.87
US$ 23.74
US$ 28.35
US$ 27.27
US$ 22.61
US$ 29.21
US$ 22.85
US$ 24.48
US$ 25.17
US$ 24.11
